Clinical trials: Osteoporosis Postmenopausal
Bone Loss, Osteoporosis
Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women
Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women.
- Trial name
- NCT01159873
- Testing
- CEP-37251
- Where
- Australia
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cephalon
Osteoporosis, Postmenopausal Osteoporosis
Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women
The purpose of this study is to determine whether BA058 (abaloparatide), a parathyroid hormone-related peptide, is effective in preventing fractures in postmenopausal women with severe osteoporosis who are at risk of fractures.
- Trial name
- ACTIVE (NCT01343004)
- Testing
- BA058 80 mcg, teriparatide
- Where
- 28 sites in United States, Argentina and 8 more
- Volunteers
- 2,463 people
- Sponsor
- Radius Health, Inc.
Osteoporosis, Postmenopausal
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women
This is an observational study to investigate the prevalence of osteoporotic fractures in post menopausal patients. Post menopausal patients who visit OS(orthopedic surgery) including GHs(general hospitals) and clinics will be…
- Trial name
- TOP (NCT01381588)
- Testing
- Fracture evaluation
- Where
- South Korea
- Volunteers
- 1,136 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Postmenopausal Osteoporosis
A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.
- Trial name
- NCT00092027
- Testing
- MK0217, alendronate sodium/Duration of Treatment: 6 months
- Volunteers
- 454 people
- Sponsor
- Organon and Co
Osteoporosis
Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily multiple-dose administration of odanacatib (MK0822).
- Trial name
- NCT00769418
- Testing
- odanacatib
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis, Post-Menopausal
Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
The purpose of this study is to measure carotid artery IMT at a single visit in a subset of women previously enrolled in the CORE (H3S-MC-GGJY) trial
- Trial name
- NCT00532246
- Testing
- raloxifene
- Where
- 5 sites in United States
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Osteoporosis, Postmenopausal
A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
The purpose(s) of this study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it when given in multiple doses, subcutaneously (SC) (by inserting a needle just under…
- Trial name
- NCT02109042
- Testing
- Blosozumab
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
This study is designed to investigate the safety and tolerability of PTH134 in healthy subjects and to assess the exposure from PTH134.
- Trial name
- NCT00676312
- Testing
- PTH134
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Novartis
Osteoporosis, Postmenopausal
Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal…
- Trial name
- NCT00790101
- Testing
- Risedronate, Raloxifene
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sanofi
Osteoporosis
A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D
The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoporosis
- Trial name
- NCT00525798
- Testing
- SMC021 Oral calcitonin
- Where
- 16 sites in United States, Brazil and 10 more
- Volunteers
- 4,665 people
- Sponsor
- Nordic Bioscience A/S
Postmenopausal Osteoporosis, Osteopenia
Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis
The overall objective of the study is to compare treatment with the ASTRA TECH Implant System, OsseoSpeed™ implant in the maxilla of postmenopausal women with and without systemic osteoporosis.
- Conditions
- Postmenopausal Osteoporosis, Osteopenia, Jaw, Edentulous, Partially
- Trial name
- NCT00745121
- Testing
- OsseoSpeed™
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 103 people
- Sponsor
- Dentsply Sirona Implants and Consumables
Post Menopausal Osteoporosis
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when…
- Trial name
- NCT01674621
- Testing
- Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg)
- Where
- 9 sites in United States, Denmark and 2 more
- Volunteers
- 250 people
- Sponsor
- Radius Health, Inc.
Osteoporosis
A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients
This is a Multi-Center, Randomized, Double-Blind, Dose Escalation, Placebo Parallel Controlled PhaseⅠClinical study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics, Immunogenicity with Multiple…
- Trial name
- NCT04435158
- Testing
- SHR-1222
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Osteoporosis
Bone Effects of Teriparatide Following Alendronate
The purpose of this study is to assess the effect of 24 months of treatment with once daily teriparatide injection (recombinant human PTH [1-34]) 20 micrograms on bone histomorphometry and architecture.
- Trial name
- NCT00191893
- Testing
- teriparatide
- Where
- 2 sites in Austria, Czechia
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
The primary objective of this study is to assess the effect of AMG 162 (denosumab) treatment on the lumbar spine BMD at month 12 and safety profile across the dose range tested (14, 60 and 100 mg SC once every 6 months) in…
- Trial name
- NCT00306189
- Testing
- 100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162
- Volunteers
- 212 people
- Sponsor
- Amgen
Osteoporosis
Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis
The purpose of this study is to assess the clinical efficacy, safety, and tolerability of ViaDerm-shPTH [1-34] transdermal delivery in comparison to subcutaneous injection of rhPTH[1-34] following 3-month treatment in…
- Trial name
- NCT00535860
- Testing
- Teriparatide
- Where
- 10 sites in Czechia, Hungary and 1 more
- Volunteers
- 104 people
- Sponsor
- TransPharma Medical
Postmenopausal Osteoporosis
Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
- Trial name
- ACTIVExtend (NCT01657162)
- Testing
- Alendronate
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 1,139 people
- Sponsor
- Radius Health, Inc.
Osteoporosis
Denosumab Adherence Preference Satisfaction Study
The primary objective is to evaluate the adherence of subjects to subcutaneous (SC) 60 mg denosumab every 6 months (Q6M) treatment compared to oral 70 mg alendronate once a week (QW) treatment at the end of treatment period 1 (12…
- Trial name
- NCT00518531
- Testing
- alendronate, denosumab
- Volunteers
- 250 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis
- Trial name
- FRAME (NCT01575834)
- Testing
- Romosozumab, Denosumab
- Where
- 218 sites in United States, Argentina and 22 more
- Volunteers
- 7,180 people
- Sponsor
- Amgen
Osteoporosis
To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females
This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women.
- Trial name
- NCT00651534
- Testing
- Ronacaleret
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline